Congratulations to our 2022-2023 MnDRIVE Neuromodulation Therapy Commercialization Fellow!

MnDRIVE Brain Conditions Logo

Join us in congratulating the recipient of the 2022-2023 MnDRIVE Neuromodulation Therapy Commercialization Fellow!

Discoveries through Industry and Commercialization Partnerships Postdoctoral Fellow

Development of a software module for the optimization of focal electrically-administered seizure therapy (FEAST)

Sina Shirinpour, Ph.D., Department of Biomedical Engineering.  Mentors are Alexander Opitz, Ph.D., Biomedical Engineering & Ziad Nahas, M.D., Psychiatry.

Depression is a serious mental health disorder which affects 5.8% of Minnesotans, and is above the national average of 4.4%. Dr. Shirinpour's research project aims to develop a software-based system to optimize electroconvulsive therapy (ECT) according to a precision-medicine approach and will be collaborating with industry partner, MECTA Corporation. Electroconvulsive therapy remains the primary treatment option for drug-resistant depression. Success in optimizing ECT to only target specific brain regions and use the minimal required energy can significantly improve treatment outcomes, reduce potential side effects, and thus quality of life for thousands of Minnesotans.